(Press-News.org) A genetic test for patients with breast cancer that helps to predict the risk of developing metastatic disease and the expected benefits of chemotherapy has been adopted quickly into clinical practice in a study of older patients and it appears to be used consistently within guidelines and equitably across geographic and racial groups, according to a study published online by JAMA Oncology.
The 21-gene recurrence score (RS) assay was approved for coverage in 2006 by the Centers for Medicare & Medicaid Services. The test is meant for patients with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer. The current guidelines recommend using the test to identify patients at low risk of developing metastatic disease who may forgo chemotherapy and patients at high risk for whom the benefits of chemotherapy may be more substantial, according to the study background.
Michaela A. Dinan, Ph.D., of the Duke University School of Medicine, Durham, N.C., and coauthors examined trends in the use of the test among Medicare beneficiaries diagnosed with breast cancer between 2005 and 2009. The authors used patient records from a Surveillance, Epidemiology and End Results (SEER) data set with linked Medicare claims. The study included patients 66 years or older at diagnosis.
The authors identified 70,802 patients and study results indicate use of the test increased from 1.1 percent in 2005 to 10.1 percent in 2009. The majority of the tests (60.9 percent) were performed in patients who met the criteria for National Comprehensive Cancer Network-defined intermediate-risk disease (estrogen receptor-positive, lymph node negative tumors >1cm).
In the overall study population of 70,802 patients, rates of chemotherapy remained similar between 2005 (16.2 percent) and 2009 (15.9 percent). In 18,218 patients with intermediate-risk breast cancer, there was not a statistically significant increase in chemotherapy use between 2005 (8.2 percent) and 2009 (10 percent).
Use of the test was associated with patients who were younger, had fewer co-existing conditions, higher-grade disease and were married. Among patients who were younger than 70 years old with intermediate-risk disease, testing rates increased from 7.7 percent in 2005 to 38.8 percent in 2009, according to the results.
While testing seemed to be modestly higher in the Northeast, the authors found that geographic region was not otherwise associated with testing. There also was no difference in the proportion of black patients among those patients who received the test (5.7 percent) and those who did not (5.9 percent), according to the results.
"Further study is warranted in patients with breast cancer who are not included in the SEER-Medicare database, particularly younger women for whom the factors affecting chemotherapy use and assay use may differ from those observed in our study. Evolving clinical paradigms of clinical management and testing indications, including the use of the assay in node-positive disease, and their impact on costs, chemotherapy use and outcomes at the national level remain important areas of study," the study concludes.
(JAMA Oncol. Published online March 5, 2015. doi:10.1001/jamaoncol.2015.43. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: This work was supported by a grant from the Agency for Healthcare Research and Quality. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Refining Treatment Decisions in Older Patients with Breast Cancer
In a related editorial, Lisa Flaum, M.D., and William J. Gradishar, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, write: "Despite the appropriately tested population, the RS score did not result in a significant change in chemotherapy utilization in this older, intermediate-risk group, increasing from 8.2 percent to 10 percent, which was not statistically significant. This contrasts with data demonstrating a more significant change in practice patterns. The lack of change in chemotherapy utilization suggests either that the physicians have a bias about treating older patients with chemotherapy that the test did not change regardless of results, or that the test results were concordant with their pretest bias."
"For the test to have clinical utility in the older population, patients would have to possess an accurate understanding of their risk of recurrence, their life expectancy and a realistic expectation of the toxic effects related to chemotherapy (which many older patients might tolerate well). Physicians have to be willing to recommend chemotherapy to appropriate older patients who have a high RS, patients for whom they might not ordinarily be as definitive in their treatment recommendation as they would be with a younger patient," the editorial notes.
(JAMA Oncol. Published online March 5, 2015. doi:10.1001/jamaoncol.2015.32. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
INFORMATION:
Media Advisory: To contact author Michaela A. Dinan, Ph.D., call Sarah Avery at 919-660-1306 or email sarah.avery@duke.edu. To contact corresponding commentary author William J. Gradishar, M.D., call Marla Paul at 312-503-8928 or email marla-paul@northwestern.edu. An author interview will be available when the embargo lifts on the JAMA Oncology website: http://jama.md/1y9ACoK
Injecting botulinum toxin A (known commercially as Botox) appears to be a safe procedure to improve smiles by restoring lip symmetry in children with facial paralysis, a condition they can be born with or acquire because of trauma or tumor, according to a report published online by JAMA Facial Plastic Surgery.
Botulinum toxin A is an effective treatment in adults to achieve facial symmetry after facial paralysis but few investigators have described its use in children, according to the study background. Severe cases of facial paralysis can require surgical reconstruction, ...
A physician who received an experimental Ebola vaccine after experiencing a needle stick while working in an Ebola treatment unit in Sierra Leone did not develop Ebola virus infection, and there was strong Ebola-specific immune responses after the vaccination, although because of its limited use to date, the effectiveness and safety of the vaccine is not certain, according to a study appearing in JAMA.
On September 26, 2014, a 44-year-old physician from the United States caring for patients in an Ebola treatment unit in Sierra Leone experienced an accidental needle stick, ...
A new study by researchers at the Intermountain Medical Center Heart Institute has found that screening for and treating depression could help to reduce the risk of heart disease in patients with moderate to severe depression.
Researchers at the Intermountain Medical Center Heart Institute, the flagship facility for the Intermountain Healthcare system based in Salt Lake City, analyzed the health records and rates of death, coronary artery disease and stroke of more than 26,000 patients treated by Intermountain over a three-year period.
This is the first study to assess ...
A low-cost antiseptic used to cleanse the cord after birth could help reduce infant death rates in developing countries by 12%, a systematic review published in The Cochrane Library suggests. Authors of the review found that when chlorhexidine was used on babies born outside of a hospital, it reduces the number of newborn babies who died or suffer from infections.
A third of deaths in newborn babies are caused by infections. As one of the World Health Organisation's Essential Medicines, chlorhexidine has been used in hospitals and other medical settings to prevent bacterial ...
More young people than ever are getting most of their information about sexual matters from school, but the majority feel they are not getting all the information they need, and men in particular are missing out, according to new research published in BMJ Open.
The findings come from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3), the largest scientific study of sexual health and lifestyles in Britain. The research was carried out by UCL (University College London), the London School of Hygiene & Tropical Medicine, and NatCen Social Research. ...
CHICAGO --- Walking barefoot on sand "felt like walking on glass" for Keith Wenckowski, who has lived with type-one diabetes for more than two decades.
One of the participants in a new Northwestern Medicine study who suffered from painful diabetic neuropathy (PDN), Wenckowski finally found relief from the constant foot pain that required him to wear shoes at all times, even to the beach.
The study found that those with PDN who received two low dose rounds of a non-viral gene therapy called VM202 had significant improvement of their pain that lasted for months.
"I ...
Methane is one hot gas. It's a prominent component of natural gas, an important atmospheric gas, and a product of both biology and chemical reactions. Its presence was recently confirmed in the atmosphere of Mars by NASA's Curiosity Rover and it has made the news both as a critical greenhouse gas and as a groundwater contaminant resulting from fracking. Yet, while methane seems to be everywhere, many questions remain about the reactions that produce and consume this high-energy compound.
"Deciphering the many pathways by which methane is produced is one of the holy grails ...
For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. A team of scientists at the Broad Institute and MIT's David H. Koch Institute for Integrative Cancer Research have pioneered the use of this technology to "knock out," or turn off, all genes across the genome systematically in an animal model of cancer, revealing genes involved in tumor evolution and metastasis and paving the way for similar studies in other cell types and diseases. The work appears online March 5 in Cell.
"Genome-scale ...
A molecule found in some plants can combat weight gain induced by a high-fat diet, but only in female mice, not males. 7,8-dihydroxyflavone (7,8-DHF) is thought to mimic the effects of a growth factor induced by exercise.
Emory researchers led by Keqiang Ye, PhD, have shown that female mice treated with 7,8-DHF could consume a high-fat diet without gaining weight. In the mice, 7,8-DHF could increase energy expenditure by acting on muscle cells, without suppressing appetite.
"An equivalent diet pill in humans would allow people to maintain a healthy weight, despite a ...
Did you know that our body produces its own marijuana-like compound to protect us against anxiety? A study led by Ottawa researchers, published today in Neuron, reveals a new biological pathway that regulates this system and suggests that a drug currently in clinical trials to treat obesity might also provide an attractive way to combat anxiety disorders.
"Anxiety and obesity are growing problems in society," said Dr. Hsiao-Huei Chen, associate professor of medicine at the University of Ottawa and a senior scientist at the Ottawa Hospital Research Institute. "Not only ...
